BRCA2 and breast carcinoma: Inhibition of BRCA1 and BRCA2 expression by FR suggested a synergistic cytotoxic effect with olaparib based on the fact that this PARP1 inhibitor is effective in breast cancer with genetic deficiencies in BRCA1 or BRCA2 [44].